Navigating the Challenges of Shared Decision‐Making in Amyloid Immunotherapy for Alzheimer's Disease
European Journal of Neurology · 2026-11 · 33 (11)
DOI: 10.1111/ene.70800 ↗At a glance
Journal article in European Journal of Neurology, published online on 2026-11-02. Written by Grâce François and 5 co-authors. Institution: Lille Neuroscience & Cognition, UMR-S 1172, LabEx DISTALZ, Université de Lille, Inserm, CHU Lille, Lille, France. Major MEDLINE topics: Alzheimer Disease, Decision Making, Shared, Immunotherapy, Patient Participation. 70 references. The full text is freely available (open access, CC BY-NC 4.0).
Topics: Demenz
Abstract (original language)
Background
Anti‐amyloid therapies (AATs), such as lecanemab and donanemab, represent a major therapeutic development for early Alzheimer's disease (AD). However, safety risks and uncertainties regarding long‐term effects make treatment decisions complex. These decisions arise when patients remain legally capable of providing informed consent but may experience cognitive vulnerabilities affecting their ability to engage in complex decisions. Shared decision‐making (SDM) is therefore particularly relevant, yet its implementation raises ethical and practical challenges.
Methods
This position paper draws on a multidisciplinary reflection on decision‐making, informed consent, and cognitive vulnerability in early AD and AATs. The authors, with expertise in neurology, geriatrics, law, and history, examined challenges to patient participation and developed a relational framework integrating SDM and supported decision‐making.
Results
Impairments in memory, insight, and executive function, together with cognitive biases, stigma, and the complexity of AAT‐related information, may compromise patient participation despite preserved legal capacity. Formal capacity assessments and improved information delivery may address some difficulties but are unlikely to provide comprehensive support. We propose a relational framework involving assessment of patients' cognitive vulnerabilities, values, preferences, and informational needs; tailored information; and involvement of a patient‐designated care partner to support information exchange, deliberation, and expression of preferences. Consent should be iterative, with safeguards to preserve autonomy and confidentiality, prevent coercion, and avoid excluding socially isolated individuals.
Conclusion
Combining SDM with supported decision‐making may provide an ethical and practical framework for autonomous treatment decisions regarding AATs in early AD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Lille Neuroscience & Cognition, UMR-S 1172, LabEx DISTALZ, Université de Lille, Inserm, CHU Lille, Lille, France.
- Recherches en éthique et épistémologie, U1018, Espace de Réflexion Éthique de la Région Île-de-France, Université Paris-Saclay, CESP, INSERM, Gustave Roussy, Villejuif, France.
- Faculté de médecine, Université de Montréal, Centre de Recherche, Institut de Gériatrie de Montréal, Québec, Canada.
- Nantes Université, INSERM, CHU Nantes, F-44093 Nantes, Hôpital Fondation Rothschild, Paris, France.
- Laboratoire Droit et Changement Social, UMR 6297, Nantes Université, CNRS, Nantes, France.
ORCID profiles: Grâce François, Robin Michalon, Thomas Tannou, Philippe Damier, Sonia Desmoulin, Thibaud Lebouvier
Cite
APA
François, G., Michalon, R., Tannou, T., Damier, P., Desmoulin, S., & Lebouvier, T. (2026). Navigating the Challenges of Shared Decision‐Making in Amyloid Immunotherapy for Alzheimer's Disease. European Journal of Neurology, 33(11). https://doi.org/10.1111/ene.70800
Vancouver
François G, Michalon R, Tannou T, Damier P, Desmoulin S, Lebouvier T. Navigating the Challenges of Shared Decision‐Making in Amyloid Immunotherapy for Alzheimer's Disease. European Journal of Neurology. 2026;33(11). doi:10.1111/ene.70800
BibTeX
@article{Franois2026,
author = {François, Grâce and Michalon, Robin and Tannou, Thomas and Damier, Philippe and Desmoulin, Sonia and Lebouvier, Thibaud},
title = {Navigating the Challenges of Shared Decision‐Making in Amyloid Immunotherapy for Alzheimer's Disease},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {11},
doi = {10.1111/ene.70800}
}
EUVIMED